Physician profile
John Peck
NPI 1891895538
$2,910.01
in general payments reported to CMS, 2019-2025
33 companies · $77.87 in 2025
The $77.87 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $327 · 2021: $314 · 2022: $250 · 2023: $247 · 2024: $1,473 · 2025: $77.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $916 · Travel and Lodging: $835 · Education: $47.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $915.53 |
| Travel and Lodging | $834.91 |
| Education | $47.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,117.28 | 2024 | Aquabeam System |
| Astellas Pharma US INC | $449.22 | 2019-2023 | Myrbetriq |
| Antares Pharma, INC. | $175.32 | 2020-2024 | Xyosted, Nocdurna, Tlando |
| Abbvie INC. | $156.64 | 2020-2024 | |
| Sumitomo Pharma America, INC. | $141.20 | 2023-2025 | Gemtesa, Orgovyx |
| Tolmar, INC. | $124.95 | 2023-2024 | |
| Endo Pharmaceuticals INC. | $90.31 | 2020-2023 | Xiaflex |
| Clarus Therapeutics INC. | $61.83 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $53.13 | 2019-2022 | |
| Boston Scientific Corporation | $49.49 | 2019-2023 | |
| Axonics, INC. | $45.66 | 2022-2024 | Axonics |
| Neotract INC. | $39.62 | 2020 | |
| Olympus America INC. | $36.70 | 2022-2025 | Itind System |
| Coloplast Corp | $35.03 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $29.75 | 2022-2023 | Seglentis |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $29.24 | 2023 | |
| Acerus Pharmaceuticals Corporation | $25.37 | 2020 | |
| Azurity Pharmaceuticals, INC. | $21.60 | 2025 | Azmiro |
| Teleflex LLC | $21.25 | 2021 | |
| Myovant Sciences INC. | $19.29 | 2022 | |
| Civco Medical Instruments | $19.07 | 2025 | |
| Immunitybio, INC. | $18.48 | 2024 | |
| Progenics Pharmaceuticals, INC. | $17.86 | 2023 | Pylarify |
| Urovant Sciences INC | $17.06 | 2022 | |
| Cook Medical LLC | $16.21 | 2019 | |
| Telix Pharmaceuticals | $16.21 | 2024 | Illuccix |
| Endo USA, INC. | $15.19 | 2024 | Xiaflex |
| Janssen Biotech, INC. | $14.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.07 | 2024 | Uzedy |
| Verity Pharmaceuticals INC. | $14.04 | 2024 | Tlando |
| Metuchen Pharmaceuticals | $13.18 | 2020 | |
| Dendreon Pharmaceuticals LLC | $10.89 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$739.66 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Peck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.